SCHEMBL5629016

SCHEMBL5629016

O=C(O)c1ccccc1Nc1ccc2ncncc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 3/20 0.55
EGFR P00533 2/20 0.50
DAPK3 O43293 4/20 0.49
PIM1 P11309 4/20 0.49
CDK2 P24941 4/20 0.49
FLT3 P36888 4/20 0.49
GSK3B P49841 4/20 0.49
CDK9 P50750 4/20 0.49
CDK5 Q00535 4/20 0.49
DYRK1A Q13627 4/20 0.49
HIPK2 Q9H2X6 4/20 0.49
STK17A Q9UEE5 4/20 0.49
MELK Q14680 3/20 0.49
PRKD3 O94806 3/20 0.49
PAK4 O96013 3/20 0.49
CSNK1A1 P48729 3/20 0.49
JAK3 P52333 3/20 0.49
MAP4K2 Q12851 3/20 0.49
PKN2 Q16513 3/20 0.49
CLK4 Q9HAZ1 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5628546 0.83 CDC25B (0.50) EGFRKDM4EMEN1ALDH1A1TP53
SCHEMBL2485382 0.79 EGFR (0.63) EGFRMAPK1PTGS1PTGS2KDM4E
SCHEMBL10144151 0.76 FABP4 (0.62) TAS2R14FABP4CTSVCTSLFTO
SCHEMBL29985822 0.75 EGFR (0.61) EGFRMEN1NPC1MAPTKMT2A
SCHEMBL5495689 0.74 JAK2 (0.63) EGFRJAK2ABL1CSF1RIGF1R
SCHEMBL27881434 0.74 EGFR (0.59) EGFRMEN1NPC1MAPTKMT2A
SCHEMBL18109767 0.73 FABP4 (0.85) DAPK3PIM1CDK2FLT3GSK3B
SCHEMBL5425226 0.73 ROCK2 (0.74) MAPK8EGFRDAPK3PIM1CDK2
SCHEMBL28133218 0.72 FABP4 (0.75) TAS2R14FABP4CTSVCTSLFTO
SCHEMBL29972584 0.72 AR (0.51) EGFRROCK2KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307088-B2 Substituted anthranilic amide derivatives and methods of use AMGEN INC. (US) 2007-12-11 US disclosed
EP-1519921-A2 SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE Amgen Inc. (US) 2005-04-06 EP disclosed
US-20040087568-A1 Substituted anthranilic amide derivatives and methods of use AMGEN INC. 2004-05-06 US disclosed
WO-2004005279-A2 SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087568-A1 Substituted anthranilic amide derivatives and methods of use AADAC, ASPH, EGLN3 MAPK8 1267/4885EGFR 1056/4885DAPK3 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.